Compare AMKR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | PRAX |
|---|---|---|
| Founded | 1968 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 9.6B |
| IPO Year | 1997 | 2020 |
| Metric | AMKR | PRAX |
|---|---|---|
| Price | $71.06 | $328.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $64.50 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 3.8M | 315.1K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 4.90 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $4,052,650,000.00 | N/A |
| Revenue This Year | $13.24 | N/A |
| Revenue Next Year | $9.90 | $7,758.26 |
| P/E Ratio | $209.64 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.18 | $34.89 |
| 52 Week High | $79.23 | $354.87 |
| Indicator | AMKR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 65.34 | 51.96 |
| Support Level | $40.96 | $282.49 |
| Resistance Level | N/A | $353.83 |
| Average True Range (ATR) | 4.02 | 19.33 |
| MACD | -0.05 | -1.74 |
| Stochastic Oscillator | 61.13 | 42.19 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.